Accueil   Diary - News   All news VirPath and VirHealth have validated the effectiveness of air purifiers against SARS-CoV-2

VirPath and VirHealth have validated the effectiveness of air purifiers against SARS-CoV-2

 

 

 

 

 

 

 

The public-private VirPath / VirHealth consortium, hosted within Lyonbiopole Innovation Centre, reported the conclusions of its study to the Auvergne-Rhône-Alpes Region. The study consisted of testing the effectiveness of two air purifiers against SARS-CoV-2 and of studying the persistence of this virus on HEPA filters. And the results speak for themselves: these devices eliminate up to 99.9% of infectious viruses with a filter persistence of up to 48 hours.

 

For more than a year, the Auvergne-Rhône-Alpes ecosystem as well as Lyonbiopole health competitiveness cluster have been working together to actively seek innovative solutions, both clinical and technological, to COVID-19. Building on existing partnerships, Lyonbiopole and the VirPath laboratory collaborated on a study aimed at measuring the effectiveness of innovative air purification devices, a solution which is being tested in high schools in the region.

 

In January 2021, an evaluation of the effectiveness of two filtering air purifying devices against SARS-CoV-2 began, at the request of the Auvergne-Rhône-Alpes Region, which has invested €184K in this project. This study was carried out by the VirPath laboratory, an internationally recognised specialist in pathogenic respiratory viruses, and VirHealth, a company specialising in the evaluation of the virucidal and antiviral activities of disinfectant products, equipment and technologies. Its results are particularly positive, with up to 99.9% filtration of the virus in 20 minutes of use (10 air recirculation cycles), and complete disappearance of infectious viruses on the filters within 48 hours. Following the presentation of these conclusions, this solution will be rolled-out in several public establishments in the region, offering a new weapon to limit the spread of the virus. 

 

 

 

 

 

 

Read the press release (french)